ReviewHuman vaccines & immunotherapeutics2017
A safe and efficient BCG vectored vaccine to prevent the disease caused by the human Respiratory Syncytial Virus.
Review in Human vaccines & immunotherapeutics, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 26 citations in OpenAlex.
- A recombinant BCG with surface-displayed antigen induces humoral and cellular immune responses.Scientific reports · 2025Article
- Beyond Tuberculosis: The Surprising Immunological Benefits of the Bacillus Calmette-Guérin (BCG) Vaccine in Infectious, Auto-Immune, and Inflammatory Diseases.Pathogens (Basel, Switzerland) · 2025Review
- Review
- Engineering a dual vaccine against COVID-19 and tuberculosis.Frontiers in cellular and infection microbiology · 2023Article
- Research progress on specific and non-specific immune effects of BCG and the possibility of BCG protection against COVID-19.Frontiers in immunology · 2023Review
- Current GMP standards for the production of vaccines and antibodies: An overview.Frontiers in public health · 2022Review
- Effects of Recombinant IL-35-BCG on Treg/Th17 Cell Imbalance and Inflammatory Response in Asthmatic Newborn Mice Induced by RSV.Inflammation · 2021Article
- The Future of Respiratory Syncytial Virus Disease Prevention and Treatment.Infectious diseases and therapy · 2021Review
- A Recombinant BCG Vaccine Is Safe and Immunogenic in Neonatal Calves and Reduces the Clinical Disease Caused by the Respiratory Syncytial Virus.Frontiers in immunology · 2021Article
- BCG vaccination induced protection from COVID-19.The Indian journal of tuberculosis · 2021Review
- The BCG Vaccine for COVID-19: First Verdict and Future Directions.Frontiers in immunology · 2021Review
- Review
- Could BCG Vaccination Induce Protective Trained Immunity for SARS-CoV-2?Frontiers in immunology · 2020Article
- Induction of Trained Immunity by Recombinant Vaccines.Frontiers in immunology · 2020Review
- The long road to protect infants against severe RSV lower respiratory tract illness.F1000Research · 2019Review
- Cytokines in the Respiratory Airway as Biomarkers of Severity and Prognosis for Respiratory Syncytial Virus Infection: An Update.Frontiers in immunology · 2019Review
- Immune-Modulation by the Human Respiratory Syncytial Virus: Focus on Dendritic Cells.Frontiers in immunology · 2019Review
- Prevention of Pediatric Respiratory Syncytial Virus Lower Respiratory Tract Illness: Perspectives for the Next Decade.Frontiers in immunology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The human Respiratory Syncytial Virus (hRSV) causes lower respiratory tract infections including pneumonia and bronchiolitis. Such infections also cause a large number of hospitalizations and affects mainly newborns, young children and the elderly worldwide. Symptoms associated with hRSV infection are due to an exacerbated immune response characterized by low levels of IFN-γ, recruitment of neutrophils and eosinophils to the site of infection and lung damage. Although hRSV is a major health problem, no vaccines are currently available. Different immunization approaches have been developed to achieve a vaccine that activates the immune system, without triggering an unbalanced inflammation. These approaches include live attenuated vaccine, DNA or proteins technologies, and the use of vectors to express proteins of the virus. In this review, we discuss the host immune response to hRSV and the immunological mechanisms underlying an effective and safe BCG vectored vaccine against hRSV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.